Glucagon-like peptide-1 receptor agonists (GLP1RA) are incretin agents initially designed for the treatment of type 2 diabetes mellitus but because of pleiotropic actions are now used to reduce cardiovascular disease in people with type 2 diabetes mellitus and in some instances as approved treatments for obesity. In this review we highlight the biology and pharmacology of GLP1RA. We review the evidence for clinical benefit on major adverse cardiovascular outcomes in addition to modulation of cardiometabolic risk factors including reductions in weight, blood pressure, improvement in lipid profiles, and effects on kidney function. Guidance is provided on indications and potential adverse effects to consider. Finally, we describe the evolving landscape of GLP1RA and including novel glucagon-like peptide-1-based dual/polyagonist therapies that are being evaluated for weight loss, type 2 diabetes mellitus, and cardiorenal benefit.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cjca.2023.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential effect of nonpharmacological interventions according to prediabetes phenotype: Systematic review and meta-analysis of randomized clinical trials.
Diabet Med
January 2025
Universidad Científica del Sur, Lima, Peru.
Background And Aims: Impaired glucose intolerance (IGT) and impaired fasting glucose (IFG) are totally different. Lifestyle modification is effective in moving from prediabetes to normoglycaemia. There is a lack of information showing the effect of lifestyle modification according to each prediabetes and assessing its effect on the degree of reversibility to normoglycaemia and on cardiometabolic markers.
View Article and Find Full Text PDFTriglyceride glucose index-body mass index as a predictor of coronary artery disease severity in patients with H-type hypertension across different glucose metabolic states.
Diabetol Metab Syndr
January 2025
Department of Cardiology, Wuhan Third Hospital & Tongren Hospital of Wuhan University, Wuhan, 430074, Hubei, China.
Background: The triglyceride glucose-body mass index (TyG-BMI) is considered to be a reliable surrogate marker of insulin resistance (IR). However, limited evidence exists regarding its association with the severity of coronary artery disease (CAD), particularly in hypertensive patients with different glucose metabolic states, including those with H-type hypertension. This study aimed to investigate the relationship between TyG-BMI and CAD severity across different glucose metabolism conditions.
View Article and Find Full Text PDFEffects of Cirsium japonicum var. maackii on avelliation of metabolic disease by improving insulin resistance.
Lab Anim Res
January 2025
Department of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University, The 1st Veterinary R&D Building Rm 301, 79 Gobong-ro, Iksan-si, Jeollabuk-do, 54596, Republic of Korea.
Background: Metabolic syndrome (MetS) refers to a group of risk factors that cause health problems, such as obesity, diabetes, dyslipidemia, and hyperglycemia. MetS is characterized by insulin resistance, which leads to abnormal insulin sensitivity. Cirsium japonicum var.
View Article and Find Full Text PDFCritical updates on oral insulin drug delivery systems for type 2 diabetes mellitus.
J Nanobiotechnology
January 2025
School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Bandar Sunway, Selangor, Malaysia.
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin resistance, leading to elevated blood sugar levels. Exogenous insulin can counteract the diminished response to insulin and effectively controlling blood glucose levels, thereby minimizing diabetes-related complications. However, given the injectable nature of exogenous insulin, apprehensions regarding its safety and the difficulties associated with its administration have hindered its widespread and prompt utilization.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!